Please login to the form below

Not currently logged in
Email:
Password:

Zerbaxa

This page shows the latest Zerbaxa news and features for those working in and with pharma, biotech and healthcare.

Merck defeated in antibiotic patent case in US

Merck defeated in antibiotic patent case in US

In addition to Cubicin, buying Cubist has also given Merck Sivextro (tedizolid phosphate) - anther treatment for skin and skin structure infections, and Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal and urinary ... Neither of these

Latest news

  • Merck prepares filings for Clostridium antibody Merck prepares filings for Clostridium antibody

    Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

  • Shire and Baxalta drugs among CHMP's latest recommendations Shire and Baxalta drugs among CHMP's latest recommendations

    Merck Sharp &Dohme's Zerbaxa (ceftolozane / tazobactam) for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections. •

  • Relief as study finds no cardiovascular risk with Januvia Relief as study finds no cardiovascular risk with Januvia

    Meanwhile, first-in-class insomnia therapy Belsomra (suvorexant) and new antibiotic Zerbaxa (ceftolozane/tazobactam) also got off to a good start, according to chief executive Kenneth Frazier.

  • Actavis gets FDA nod for new antibiotic Actavis gets FDA nod for new antibiotic

    Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    FDA backs Cubist's antibiotic Zerbaxa. Combination cephalosporin and beta lactamase inhibitor wins US approval. ... The Zerbaxa approval brings the number of novel antibiotics approved by the FDA in 2014 to four.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2014 Pharma deals during December 2014

    Buoyed with the news in mid-December of the FDA approval of another Cubist antibiotic, Zerbaxa (ceftolozane/tazobactam), for the treatment of various Gram-negative bacterial infections, it looks as if

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics